The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11142801 B1

PDF
Full Text
Expired
Date of Patent:
Oct. 12, 2021

Filed:

Oct. 07, 2016
Applicants:

Japanese Foundation for Cancer Research, Koto-ku, JP;

Sekisui Medical Co., Ltd., Chuo-ku, JP;

Inventors:

Masami Arai, Koto-ku, JP;

Sachio Nomura, Koto-ku, JP;

Yuriko Nemoto, Inzai, JP;

Takuya Yotani, Ryugasaki, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12P 19/34 (2006.01); C12Q 1/6886 (2018.01); G01N 30/88 (2006.01); G01N 30/02 (2006.01); C12Q 1/68 (2018.01); C12N 15/09 (2006.01); C12N 15/00 (2006.01); C12Q 1/6806 (2018.01); B01J 20/281 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12N 15/00 (2013.01); C12N 15/09 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6806 (2013.01); G01N 30/02 (2013.01); G01N 30/48 (2013.01); G01N 30/88 (2013.01); C12Q 2600/154 (2013.01);
Abstract

It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.


Find Patent Forward Citations

Loading…